Moleculin Biotech announces interim data in annamycin trials

Moleculin Biotech provided a preliminary update on recent clinical activity and expected near term milestones across its clinical development pipeline in its quarterly filing with the Securities and Exchange Commission. “Having 38% of subjects with a median age of 68 in our MB-106 AML study receiving a full course of Annamycin show a complete response with durability of up to approximately 8 months and counting, we believe, is exceptional while also demonstrating no cardiotoxicity,” Dr. Paul Waymack, Senior Chief Medical Officer said. “Adding to this, we are showing in our Phase 1B/2 study with Annamycin treating soft tissue sarcoma with pulmonary metastases for subjects with no limit on prior therapies PFS of 2.2 months or better for 59% of the subjects. In subjects with fewer prior therapies and dosed with Annamycin at or below 330 mg/m2, this increased to 78% and, additionally, we are showing PFS of 3.4 months for 56% of these subjects. Having a preliminary median of 11.3 months of overall survival once the subject has entered into our Phase 1B study, is exciting as these subjects were heavily pre-treated. For the overall study, we have an opportunity for the Extended OS and PFS data to get better as subjects continue to be monitored.”